Company intelligence / Profile preview

Prasidiux

Austin, Texas, USA

Ownership: Private
Development stage: Other

Overview

Prasidiux is a biotechnology company focused on the development of masked cytokine therapies for the treatment of cancer. Utilizing a proprietary platform, the company engineers "pro-cytokines" that are designed to remain inactive in the bloodstream, thereby minimizing systemic side effects. These molecules are specifically activated by proteases found within the tumor microenvironment, allowing for localized immune stimulation. Prasidiux's lead programs include masked versions of Interleukin-2 (IL-2) and Interleukin-12 (IL-12), aimed at providing safer and more effective options for patients with solid tumors.

Therapeutic areas: Oncology
Modalities: Recombinant proteinCytokineMasked cytokine
Industry: Biotech

Partnerships

University of Texas at Austin

Beyond the preview

Go deeper on Prasidiux.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Prasidiux.

Explore the full profile